Abstract: Circular RNAs (circRNAs) are a distinct family of RNAs derived from the non-regular process of alternative splicing. CircRNAs have recently gained interest in transcriptome research due to their potential regulatory functions during gene expression. CircRNAs can act as microRNA sponges and affect transcription through their complex involvement in regular transcriptional processes. Some early studies also suggested significant roles for circRNAs in human diseases, especially cancer, as biomarkers and potential clinical targets. Therefore, there is a great need for laboratory scientists to translate these findings into clinical tools to advance testing for human diseases. To facilitate a better understanding of the promise of circRNAs, we focus this review on selected basic aspects of circRNA research, specifically biogenesis, function, analytical issues regarding identification and validation and examples of expression data in relation to human diseases. We further emphasize the unique challenges facing laboratory medicine with regard to circRNA research, particularly in the development of robust assays for circRNA detection in different body fluids and the need to collaborate with clinicians in the design of clinical studies.
Introduction
Over the last decade, whole-genome sequencing studies have revealed that a significant part of the human genome encodes transcripts that are not translated into proteins. These non-coding RNAs comprise a large group of different small (<200 nucleotides) to long (>200 nucleotides) RNA molecules such as microRNAs (miRNAs), piwi-interacting RNAs and large intergenic non-coding RNAs [1] . A new class of RNAs, named circular RNAs (circRNAs) in reference to their structure, was characterized and validated within the last 6 years after Salzman et al. [2] discovered in 2012 that circRNAs are ubiquitously expressed and highly conserved. CircRNAs are single-stranded covalently closed RNA molecules lacking 5′-3′ polarization and the characteristic poly(A) tail of linear RNA [3] .
Covalently closed RNA rings were first discovered in viroids in the 1970s using electron microscopy [4] . Until the early 2010s, they were regarded as transcriptional trash due to mis-splicing, similar to non-coding RNAs [5] . However, the development of high-throughput sequencing technologies and the considerable advances in bioinformatics and systems biology in recent years has enabled researchers to identify human circRNAs as stable and abundant splicing products [6] . Similar to noncoding RNAs, circRNAs function as critical gene expression regulators in most cellular processes in both healthy and diseased tissues. The continuous increase of circRNArelated publications in clinical medicine highlights the potential development of circRNAs as promising biomarkers and therapeutic targets (Figure 1 ), suggesting that there are new diagnostic opportunities within laboratory medicine as well as analytical challenges in translating novel molecular insights into the potential for non-invasive biomarkers.
This review should, therefore, draw the attention of clinical chemists and laboratory physicians to this rapidly developing field. The aim of this short overview is to focus on recent progress in circRNA research and to make the scientific community of laboratory medicine aware of this and future perspectives. Some particular issues facing circRNA research are shown through the example of renal cell carcinoma using our own data [7] .
CircRNA characteristics and biogenesis
A major characteristic of circRNAs is how they are formed, which occurs through a back-splice junction that joins the downstream 3′-end of an RNA sequence with the upstream 5′-end during splicing [3] . CircRNAs result from an alternative splicing process in addition to the regular canonical splicing mechanism ( Figure 2 ). The number of circRNAs differs between cell types. Approximately 500-17,000 circRNAs have been found in 15 distinct cancerous and non-cancerous cell lines, totaling ~47,000 circRNAs [6, 10] . Approximately 80%-90% of circRNAs in clinically relevant human tissues are derived from exonic gene sequences [11] . This relevance is also shown in the example of renal cell carcinoma ( Figure 3A ). Exonic circRNAs are usually composed of 1-5 exons [8, 12] . However, intronic, antisense and intergenic genomic regions can also serve as sources for circRNAs (Figures 2   and 3A) . CircRNAs can also originate from a single host gene and can contain the same back-splice junction, forming multiple circRNA isoforms [10] . In the case of renal cell carcinoma, ~53% and 93% of host genes show more than one but less than five circRNAs, respectively ( Figure 3B ). However, more than 15 circRNAs can be derived from one host gene.
Several possible mechanisms have been suggested for the biogenesis of circRNAs, which is regulated by cis-and trans-acting factors that control splicing [9] . Cis-regulatory elements include canonical splice sites bracketing the exons, exon length and position and the length of the flanking introns as well as reverse complementary sequences within introns. The majority of mammalian circ RNAs are processed from internal exons with long flanking introns containing reverse complementary sequences [6, 13] . These complementary sequences can be repetitive, such as ALU repeats in humans, b1 repeats in mice and other repeats in drosophila or non-repetitive sequences as short as 30-40 nucleotides [6, [13] [14] [15] [16] . The pairing of these sequences strongly promotes circRNA production and is competitive. Pairing within one intron favors canonical splicing, whereas pairing of two flanking exons promotes circRNA production. The existence of several complementary regions results in the production of alternative competing circRNAs. However, not all circ RNAs require intron pairing, especially in non-mammalian organisms. In Schizosaccharomyces pombe, for example, circRNAs are produced from an exon-containing lariat precursor [17] . Lariats are noose-like intronic RNA structures that have a 2′-5′ connection creating a circle and tail formed by the 3′ region. In lariat-driven back-splicing of exonic circRNAs, the downstream 3′-and the upstream 5′-ends of two exons are connected through spliceosomeregulated exclusion of intronic lariats.
In addition, RNA-binding proteins (RBPs), such as the muscleblind-like splicing regulator 1 (MBL) [18] , the KH domain containing RNA binding factor (QKI) [19] or the RNA specific adenosine deaminase (ADAR1) [15, 20] , can act as trans-factors during circRNA biogenesis. RBPs can facilitate, control or inhibit intron pairing independent of complementary sequences within the exons.
Biogenesis of circRNA can occur post-or co-transcriptionally. Host gene-independent expression has been described, for example, during cardiac differentiation, indicating that their biogenesis is at least partially independent of each other [21] . Although circRNA levels are generally lower than linear RNA levels and the kinetics of back-splicing is slower than the kinetics of canonical splicing, some circRNAs are highly abundant in specific cell types and tissues or are dependent on cellular and developmental states, suggesting the functional relevance of these molecules [6, 10, 12] .
Biological functions of circRNAs
The striking expression differences of circRNAs are an indication of the possible functional relevance of these molecules. Recent investigations have shown that circ RNAs can interfere with several molecular processes or are essentially attributed therein. Although circRNA research is at a very early stage, it is becoming apparent that their effects are based on their miRNA and protein binding properties as well as on their potential ability to modulate transcription and translation. Therefore, circRNAs can influence both nuclear and cytoplasmic processes. CircRNAs can act as miRNA sponges, inhibit the cellular effect of miRNAs by binding them and thus competing with miRNA:mRNA binding [6, 12, [22] [23] [24] ; therefore, the inhibited mRNA targets can be expressed again. The first discovered miRNA-sponging circRNA is derived from the gene CDR1 (cerebellar degeneration related protein 1) and regulates miRNA-7 and miR-671 in the brain [12, 22, 24] . CircHIPK3 (homeodomain interacting protein kinase 3), another miRNA sponge, has been functionally associated with cancer progression [6, 23] . CircHIPK3 is highly expressed in cancer tissue, has multiple miR-124 binding sites and controls proliferation in cancer cell lines [6, 23] . The miRNA-binding capacity of circRNAs has also been correlated with their ability to act as transporters of miRNAs from the nucleus into the cytoplasm and finally into the extracellular compartment through exosomes [25] . CircNet (http://circnet. mbc.nctu.edu.tw) and CircInteractome (https://circinteractome.nia.nih.gov) are useful web tools to screen for probable miRNA binding sites of a candidate circRNA [26, 27] . Tissue-specific data selection is also possible. These databases comprise sequencing data from numerous Trans-factors, such as RNA-binding proteins, can also promote or inhibit circRNA production. MBL and QKI, for example, bind to flanking introns to promote circRNA production, whereas adenosine-to-inosine editing by ADAR1 prevents pairing of flanking introns to inhibit circRNA production. (Adapted from [8, 9] .) RNA samples of several studies that enable the user to find the miRNA binding sites of a given circRNA (Supplementary Table S1 ). The above-mentioned circRNAs showed possible effects on cellular processes by sponging specific miRNAs. Even more circRNAs are likely able to sponge miRNAs [27] . However, the exact functions of most circRNAs have yet to be proven experimentally and require further exploration.
CircRNA biogenesis has also been shown to compete with canonical splicing, creating an mRNA trap function [28] . This feature has been most clearly shown for mbl/ MBLN1, which is circularized in flies and humans [18] . Mbl has multiple binding sites in the flanking introns of the circularized exon and in the circRNA itself. When expressed, MBL protein has been shown to promote production of the circRNA by binding to the flanking introns. In turn, circMbl sponges up excess protein to regulate MBL protein levels [18] .
Data show that intron-containing circRNAs, which are predominantly localized in the nucleus, enhance the trans cription of their parental genes by interacting with RNA polymerase II, likely in association with the small nuclear U1 snRNA [29] . Another function of circRNAs related to transcription is that they bind to the DNA of their host gene, a phenomenon demonstrated in plants but not in eukaryotes until now [30] . This DNA-circRNA hybrid can also impair polymerase II activity.
With regard to the potential translation ability of circRNAs, certain circRNAs were recently shown to be associated with translating ribosomes [31] . The authors provided strong evidence for a 5′-cap-independent translation of circRNAs based on results of different experiments, including the detection of circRNA-encoded proteins and specific peptides. Using mass spectrometry, other authors also identified peptides that are unique to circRNA-encoded proteins [32] .
Analytical challenges in circRNA research
Challenges exist in the determination of circRNAs, specifically regarding their sensitivity and specificity. The reasons for these challenges include the following: (a) the particularity of back-splice junctions in circRNAs; (b) the fact that the generation of circRNA and linear RNA from the same parent genes results in matching sequence portions, as exons are shared between the circRNA and the annotated mRNA; and (c) the frequent low abundance of circRNAs in comparison to the abundance of linear transcripts. Problems in the determination of circRNAs are comparable, if not more complicated, than the determination of other RNA forms. Therefore, a multistep strategy is advisable and has already proven successful for the reliable validation of miRNAs or piwi-interacting RNAs [33] . Such an approach should consist of three steps as follows: (1) the discovery and identification of circRNAs, (2) the validation of those circRNAs of interest using other molecular biology-based methods and (3) their reliable quantification.
Discovery/identification of circRNAs
Two approaches are predominantly used to obtain information about circRNA expression profiles, namely, the analytical platforms of RNA sequencing (RNA-Seq) and microarray technology. 
RNA-sequencing
High-throughput RNA sequencing enables researchers not only to identify new circRNAs by screening for back-splice junctions [3, 23, 34] but also to quantify circRNA expression in different samples [23] . For the establishment of circRNA-Seq libraries, one must prepare appropriate libraries based on the characteristics of circRNAs. In contrast to mRNAs, circRNAs lack a poly(A) tail and are resistant to exonuclease RNase R [6, 35, 36] . Therefore, total RNA samples depleted of ribosomal RNA and the polyadenylated mRNA and additionally treated with RNase R are the preferred samples for circRNA-Seq library preparation [6, 8, 37, 38] . These combined purification steps result in an enrichment of circRNAs as a precondition for their specific and sensitive discovery and identification. However, libraries prepared only after the depletion of ribosomal RNA or the polyadenylated mRNA fraction, in each case without RNase R treatment, were used for annotation in most circRNA databases [11, 26, 37, [39] [40] [41] .
After sequencing, the results are mapped to a human reference genome (e.g. GRCh37/hg19 [6, 23] ) using an alignment tool (e.g. Bowtie, Bowtie2, TopHat2 [23] ), allowing for the identification of back-splice junctions via unmapped reads [12, 23, 42] . In addition, the relative expression of a circRNA candidate in cancerous versus normal tissue can be determined by calculating the normalized quotient of spliced reads per billion mappings in both samples [6] .
Although next-generation sequencing is a powerful method for displaying tissue-specific genome-wide circRNA profiles, its limitations must be considered. There can be transcription mistakes produced by the reverse transcriptase or ligation (e.g. template switching), resulting in apparent identification of circRNA [43, 44] , as well as insufficient specificity and sensitivity in circRNA detection produced by the chosen bioinformatics thresholds and algorithms [8] . Lahens and colleagues [45] highlighted extensive biases in exon-level expression analysis. Numerous circRNA detection tools are available (reviewed in [46, 47] ), but the low correspondence of the predicted circRNAs using different tools is rather unsatisfactory; however, no consensus on the most applicable tool has been reached [44] . At present, a combination of several tools has been suggested as the gold standard and is now used to establish circRNA databases [37, 40, 44] . Established circRNAs should therefore be detected by several tools.
Furthermore, the commonly used sequencing by synthesis technique (Illumina) is limited to a short-read length to avoid misreads due to random transcript errors. Therefore, the reliability of this sequencing technique is reduced for circRNAs with longer sequences (>300-500). Novel sequencing technologies termed third-generation sequencing such as the Oxford Nanopore sequencing (https://nanoporetech.com) and PacBio sequencing (https://www.pacb.com), which are based on singlemolecule sensing technologies, have distinctly longer read lengths and require shorter sequencing time. Therefore, these techniques allow the sequencing of a complete circRNA transcript. They have the potential to improve the discovery and identification of circRNAs in the future as shown in several other applications of transcriptome research [48, 49] . Nevertheless, although these techniques are able to produce longer reads, they also have higher error rates and lower quality scores [50] .
Microarray
When exploring circRNA differential expression in disease, many authors rely on microarray technology as a strong and effective screening tool for circRNA profiles [51] [52] [53] [54] [55] [56] . For example, a circRNA microarray service is offered by Arraystar (Rockville, MD, USA) for human samples and covers 13,617 circRNAs collected from landmark publications, all compiled in a single database. The enriched circRNAs, after digestion of total RNA with RNase R, are amplified, labeled with specific fluorescent circular junction probes and hybridized onto the microarray. The expression in each sample is quantified by measuring fluorescence. The results are normalized, and the differential expression of the circRNA is then quantified by calculating its fold change, for example, between normal and cancerous tissues and assessed through a volcano plot. Although circRNA sequencing can be used for the discovery of potential new circRNAs, in microarray analysis, only characterized circRNAs are detected based on the corresponding probes for the individual circRNAs on the microarray. On the other hand, a recent comparative circRNA profiling study in cervical cancer using both RNA-Seq and microarray demonstrated a higher circRNA detection efficiency of the microarray assay [57] .
Validation of potential circRNA candidates
The above-mentioned limitations of high-throughput detection of circRNAs demonstrate the need for further molecular tests to prove circularity of the identified transcript. There are several molecules with apparent backsplice junctions, such as linear RNAs with repeated exons produced by reverse transcriptase template switching, tandem duplications or RNA trans-splicing that can be mistaken for circRNAs [3] .
RT-qPCR is used as a first step to validate differentially expressed circRNA candidates in target tissue. In RT-qPCR, divergent primers are designed to detect circRNAs [27] . In contrast to convergent primers, divergent primer pairs are directed away from each other when used on linear templates, thus only producing an amplicon from molecules containing back-splice junctions. A further validation step is the enzymatic digestion of the RNA sample with RNase R [35] , RNAse H [58] , tobacco acid phosphatase or terminator exonuclease [22] . Most commonly used is the 3′-5′ exonuclease RNase R, which degrades linear RNA from the poly(A) tail but leaves circRNA intact [35] . However, researchers have found that some circRNAs seem to be less resistant to RNase R degradation than others [12, 20, 23] . Furthermore, some linear RNAs have been reported to be incompletely digested by RNase R [59] .
Sanger sequencing can also be used to validate circ RNA-specific back-splice junctions. With Sanger sequencing, the possibility that trans-spliced linear RNA might display the same sequence as a circRNA backsplice junction is important to consider [60] . However, when complemented by effective RNase R treatment in combination with other validation approaches the risk of detecting a linear RNA is minimized. Several gel electrophoresis methods have also been described for circRNA validation. Northern blotting can be used to separate circRNAs from their normal counterparts [12, 22, 61, 62] . The advantage of Northern blotting is that the specificity of the results is optimized by allowing quantification of the entire circRNA length, not just the amplicon length after RT-qPCR. Designing back-splice junction-spanning probes ensures the reliability of the results. CircRNAs also migrate poorly through highly cross-linked parts of the gel in two-dimensional gel electrophoresis [63] . The use of small interfering RNA technology and corresponding vectors suitable for the overexpression of circRNAs can then provide full functional proof of circRNAs using cell culture experiments beyond the previously mentioned analytical validation approaches [16, 27, 64] .
Collectively, although the different characteristics of circRNAs have been widely discussed as possible validation criteria [3, 8, 12, 65] , there has been no documented expert consensus on which conditions need to be met until now. Providing scientists and journal editors with at least minimum experimental information for benchmarking circRNAs is an urgent matter. According to the MIQE guidelines "Minimum information for publication of quantitative real-time PCR experiments" and "Minimum information for publication of quantitative digital PCR experiments", standards for circRNA detection must be developed [66, 67] before circRNAs can be tested as potential biomarkers in clinical studies. In addition, annotations to the experimental and functional validations of circRNAs should be included in the databases.
Quantification of circRNA expression
The above-mentioned limitations of RNA-Seq technology, including the different protocols used for library preparations and the wide array of bioinformatics tools, also explain the difficulty in obtaining comparable expression data [3, 8, 44] . Due to the importance of normalization on the evaluation of RNA-Seq data, the lack of suitable normalization procedures is an obstacle to achieving comparable data between prepared circRNA libraries [8, 68] . As mentioned above, consensus guidelines for RNA-Seq technology and RT-qPCR could help to better harmonize data.
RT-qPCR assays have long been used as reliable tools to determine disease biomarkers. Different normalization approaches using suitable reference genes, spike-in procedures or digital qPCRs allow reliable measurements of differentially expressed nucleic acids for diagnostic, prognostic or predictive purposes in tissues and biofluids [33] . Therefore, targeted RT-qPCR circRNA assays developed on the basis of accurate circRNA validation should be considered the method of choice for circRNA quantifications, especially in clinical studies. CircRNA measurements and data evaluation can be directly performed without the disadvantage of "experimental calibration" resulting from the different depletion and enrichment steps, as suggested by Guo et al. [69] . Using 96-or 384-well microplate platforms, RT-qPCR-based high-throughput procedures for selected circRNA panels can be performed. Moreover, it is necessary to verify the stability of potential reference genes between, for example, malignant and non-malignant samples [66] . Relying on frequently used but unevaluated housekeeping genes such as β-actin or glyceraldehyde-3-phosphate dehydrogenase in comparative circRNA studies leaves room for potential errors [66] . In this respect, digital qPCR technology offers the advantage of absolute quantification [67] . Higher accuracy of circRNA measurements in plasma and tissue samples has been achieved using this methodology in comparison to relative quantification with reference genes [56] .
Nomenclature
To date, an impressive variety of circRNAs, which differ by structure (only exon-, only intron-and exon-and-intron-containing circRNAs) and isoform (multiple circRNAs from one host gene) have been discovered. This variety, in addition to their analytical challenges, demands a structured and concise nomenclature, which should facilitate the communication between scientists and prevent misunderstandings in research and clinical studies. However, a uniform circRNA nomenclature, comparable to the miRNA nomenclature specified in the miRBase 21 database (www.mirbase.org), is lacking. Different principles are used in various circRNA databases that are often complemented by a rubric "alias" with circRNA identity names taken from the circBase database (http://www. circbase.org) [39, 70] (Supplementary Table S1 ). Jeck and Sharpless [3] suggested naming a new circRNA after its host gene and an attached numeric identifier in the order of its discovery. This system is currently implemented in the circNet database [26] . Another circRNA identification format consists of only a numbering system with additions such as the name of the database. However, the numbers are inconsistent between databases, and the selected sequence of numbers remains unclear. Code numbers from homemade databases, without further explanations, have also been used [51] . Likewise, the genomic position of the circRNA with the localization of the back-splice junction is also used as an identification number, but this method is difficult to use in laboratory practice and publications. Therefore, the nomenclature to date is confusing and standardization is urgently needed [3] .
Deregulated circRNA expression profiles in diseases, particularly in cancer
The detection of differentially expressed circRNAs in disease is a field of growing clinical and scientific interest. Although the function of most circRNA molecules in relation to physiology and disease has not been investigated to date, their differential expression in healthy and diseased tissues makes them promising biomarker candidates. For this purpose, deregulated circRNA candidates are identified by analyzing disease-specific circRNA expression profiles. As such, circRNAs could be used for the prevention, diagnosis, prognosis, treatment and/or follow-up of a pathological process.
Valid reports outlining the potential use of differential expression of circRNAs as a clinical tool are currently limited, although in 2017 a number of exploratory studies addressed this question. A few selected examples are given in Table 1 . Comparison of circRNA expression in several human tissues from the same donors revealed high tissue specificity of circRNA and deregulation in diseased donors [11] . Memczak and colleagues [61] presented the first evidence that circRNAs could act as circulating biomarkers in whole blood, where s pecific circRNAs were detected in a higher abundance than their linear counterparts (Table 1 , study no. 1). Because circ RNAs consist of covalently closed rings without poly(A) tails, they show a superior stability than mRNAs, which are quickly degraded in body fluids. This feature makes circRNAs very interesting as non-invasive biomarkers. Further examples of deregulated circRNA expression, both in tissue and peripheral blood samples, exist for Alzheimer's disease [71] , rheumatoid arthritis [54] , active pulmonary tuberculosis [72] and diabetes mellitus type 2 [55] (Table 1 , study nos. [2] [3] [4] [5] .
Most studies to date have addressed deregulated circRNA expression in cancer (Figure 1) . A comparative study between seven cancer types (bladder urothelial carcinoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, clear cell renal carcinoma and prostate cancer) showed an overlap of 19,071 circRNAs and confirmed the general feasibility of circRNA detection in several cancer tissues [23] . Two current reviews and a cancer-specific circRNA database provide more detailed information on the role of circRNAs in different cancers [41, 73, 74] . For example, microarray data of lung adenocarcinoma samples detected higher expression of hsa_circ_0013958 in cancer tissue than in adjacent normal tissue in the same patients (Table 1 , no. 6, [52] ). Validation experiments with RT-qPCR in 49 tissue pairs supported the microarray results. Furthermore, differential expression was confirmed in plasma samples of these patients and corresponding cancer cell lines. For hepatitis B-related hepatocellular carcinoma, microarray data showed a significant upregulation of hsa_circRNA_10338 in cancer tissue compared to expression in adjacent normal tissue (Table 1 , study no. 7 [53] ).
However, all of the examples show that these clinically oriented studies do not go beyond the concept of pilot studies and are mainly of a descriptive nature. Both analytical and clinical requirements for studies recommended in the guidelines of "Standards for Reporting of Diagnostic Accuracy Studies" and "Reporting Recommendations for Tumor Marker Prognostic Studies" including the multivariate evaluation of data have yet to be exploited [75, 76] .
Future directions for laboratory medicine: circRNAs as promising biomarkers
To date, the biological functions and clinical significance of circRNAs in disease development and physiological processes remains unclear. However, circRNAs are expressed highly specific under physiological and pathological condition [6, 10, 20] . Furthermore, experimental data prove that circRNA expression is independent from the expression of linear counterparts originating from the same gene locus [21] . These facts underline the possible regulatory function of circRNAs, leading to their potential role as disease-indicating biomarkers with special interests for clinical laboratory scientists. However, as comprehensive functional studies of circRNAs are still missing to demonstrate their biological function, it cannot be excluded that the majority of circRNAs are possibly functionless transcriptional byproducts only tolerated by the cells. Therefore, future efforts in human circRNA research will be focused on unraveling which pathways are affected by specific circRNAs, either independently or as part of a network. In the case of cancer, for example, research will focus on how circRNAs act as tumor-suppressive or oncogenic factors [77, 78] . This tissue-based biological background is strongly connected with the challenge to utilize circRNAs for the same purpose as other nucleic acids as tissue-equivalent biomarkers because circRNAs could be released from diseased tissues or organs into easily accessible bio fluids such as blood or urine [33] . Although the turnover of circRNAs and the mechanisms of their release into the extracellular compartment are unknown [79] , numerous circRNAs have been found in the cellfree body fluids of healthy individuals and specific cancer patients [42, 56, [80] [81] [82] . RNA-Seq studies and RT-qPCR measurements have shown that tumor-specific circ RNAs are enriched in serum-derived exosomes/ extra cellular vesicles but not in exosome-depleted serum [42, 82] . The presence of circRNAs in these vesicles and their specific molecular structure of covalently closed rings has been suggested as the reason for their high stability in body fluids because they are protected from RNases present in body fluids [42] . Moreover, blood cells, especially thrombocytes, contain a large number of circRNAs [61, 83] . They can be differentially released depending on the blood collection method (serum or plasma). The presence of these other sources of circRNAs could substantially interfere with the diagnostic specificity of circRNA testing.
To avoid these complications and potential errors, basic and applied researchers, in collaboration with clinicians, need to work together to translate circRNA research findings for the potential use of these circRNAs as biomarkers. The introduction of other nucleic acidbased assays into clinical practice has proven that this will be a multiphase process (Figure 4) [33] . Clinical chemists and laboratory physicians, with their specific knowledge of and experience with body fluids, should play a significant role in both the successful development of circRNAs assays and in their clinical validation. Laboratory scientists are the link between the first two (basic science) and the last two (clinical) phases of this multiphase process (Figure 4) . In this process, after the discovery and experimental validation of a circRNA as mentioned above, clinical validation must be performed using robust RT-qPCR-based assays. All variables in the preanalytical phase (sample collection, processing and storage conditions), the analytical phase (RNA isolation protocols and quantification principles) and the postanalytical phase (data evaluation and normalization strategies) that could influence the determination of circRNAs must be considered and documented with standard operating procedures [76] . More detailed information is given in Supplementary Table S2 . Special attention should be paid, based on experience with other nucleic acid-based assays, to the possible interfering effects of preanalytical factors on circRNA measurements in serum/ plasma and urine samples [33] . Although cancer studies with serum-based measurements of circRNAs have been published [42, 81, 82] , there has been no information until now on how the preparation of the sample can affect the measurements. For example, there are many miRNAs compiled in a catalogue that cannot be accurately measured in serum/plasma or urine samples containing free hemoglobin undetectable by visual inspection [84, 85] . Due to this interference, an additional quality criterion was implemented to eliminate inappropriate samples [84] . A similar approach could be established for circRNAs.
In the two clinical validation phases based on retrospective and prospective studies performed at single or at multiple centers (Figure 4) , the laboratory scientist has the main task of supervising the quality of the measurements. Based on the analytical and biological variation of data, the laboratory scientist then contributes substantially to the practice-oriented evaluation of the data [86] . 
Conclusions
CircRNAs are an interesting new class of RNAs and could potentially be used as biomarkers in the future. In contrast to early reports that circRNAs are random splicing bypro ducts, whole genome studies have shown that circRNAs are stable and that their biogenesis is tightly regulated. The expression of circRNA is highly tissue-and cell-state specific, and exploratory studies have proven the general feasibility of the concept to use circRNAs as biomarkers. Their gene regulatory function, especially as a regulator of miRNAs, also makes them putative therapeutic targets. However, several limitations must be addressed before circRNAs can be evaluated in clinical studies, including detection biases and the absence of a consensus regarding validation protocols and nomenclature. More studies are needed to understand the deregulated expression, abundance, stability and function of circRNAs in specific diseases and disease stages and to confirm if this new class of RNAs is of clinical importance. For laboratory scientists, circRNA research and its translation into clinical practice is a great challenge but also a very exciting new task.
